Brief: Arix Bioscience Updates On Iterum Proposed Nasdaq IPO

Arix Bioscience

17/05/2018 08:35

May 17 (Reuters) - Arix Bioscience PLC  ARIX.L :
    * SAYS GROUP BUSINESS ITERUM THERAPEUTICS HAS FILED AN
AMENDED
FORM S-1 WITH U.S. SEC IN RESPECT OF ITS PROPOSED IPO IN US
    * SAYS AMENDED FORM S-1 FILING STATES AN EXPECTED PRICING
RANGE
FOR PROPOSED IPO OF BETWEEN $14.00 AND $16.00 PER SHARE
    * SAYS PROPOSED MAXIMUM AGGREGATE OFFERING AMOUNT SPECIFIED
IN
FILING IS US$85.3 MILLION

Source text for Eikon:  ID:nNDL2C9p3f 
Further company coverage:  ARIX.L 

 ((Reuters.Briefs@thomsonreuters.com;))